X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KP104 is a first-in-class bifunctional biologic designed to simultaneously and selectively block both the alternative and terminal complement pathways, providing a powerful and synergistic method of targeting validated drivers of complement-mediated disease.
Lead Product(s): KP104
Therapeutic Area: Rare Diseases and Disorders Product Name: KP104
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
KP104 is a first-in-class bifunctional biologic designed to simultaneously and selectively block both the alternative and terminal complement pathways, providing a powerful and synergistic method of targeting validated drivers of complement-mediated disease.
Lead Product(s): KP104
Therapeutic Area: Immunology Product Name: KP104
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
KP104 is a first-in-class biologic with a unique dual-approach mechanism of action designed to selectively block both the alternative and terminal complement pathways.
Lead Product(s): KP104
Therapeutic Area: Rare Diseases and Disorders Product Name: KP104
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Perelman School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2022
Details:
KP104 is a bifunctional, first-in-class biologic with a unique dual-approach mechanism of action. Designed to selectively block alternative and terminal pathways, KP104 provides powerful and synergistic method of targeting validated drivers of disease in complement system.
Lead Product(s): KP104
Therapeutic Area: Rare Diseases and Disorders Product Name: KP104
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.
Lead Product(s): P014
Therapeutic Area: Immunology Product Name: P014
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Quan Capital
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
